Hypoxyprobe， Inc.是一家专注缺氧Hypoxia研究的公司，致力于为氧气调节受到干扰的恶性和正常组织疾病的诊断和治疗提供工具。该公司位于121 Middlesex Turnpike， Burlington， Massachusetts， USA 01803，是Natural Pharmacia International， Inc.（NPI）的Hypoxyprobe部门的分拆。Hypoxyprobe，Inc.源于北卡罗来纳大学教堂山分校放射肿瘤学系的James Raleigh博士与当时位于北卡罗来纳州三角研究园的NPI之间的合作。UNC Chapel Hill和NPI之间的合作最初侧重于肿瘤缺氧的临床研究。NPI大规模生产盐酸匹莫硝唑，罗利博士提供了专利抗体试剂，用于检测哌莫硝唑与人类肿瘤中缺氧细胞的结合。

对狗，大鼠和小鼠的临床前研究引起了科学界对盐酸匹莫硝唑（Pimonidazole Hydrochloride）作为缺氧标志物的兴趣日益浓厚，2002年NPI向Chemicon International颁发了为期五年的独家许可，以销售有限的动物用Hypoxypro试剂系列。2006年，NPI预计需要扩大Hypoxyprobe试剂产品线，因此终止了Chemicon的许可，并成立了Hypoxyprobe，Inc.，为动物和临床研究开发增强的试剂系列。目前，Hypoxyprobe，Inc.公司现在专注于开发基于哌莫硝唑Pimonidazole核心结构的非侵入性缺氧标志物（Hypoxia maker）和缺氧依赖性细胞毒素。

缺氧（Hypoxia）就是氧供需失衡（也就是说氧供少于氧需求）或者氧利用障碍造成的组织细胞代谢障碍。哌莫硝唑Pimonidazole 是一种缺氧标记物，用于瘤内缺氧和细胞增殖的补充性研究。Pimonidazole 通过与大分子的共价结合或通过被还原形成还原性代谢物后在缺氧细胞中积累，可用于定性和定量评估肿瘤缺氧。缺氧细胞是低氧细胞，当其存在于肿瘤中时具有放射抗性和化学抗性。 哌莫硝唑Pimonidazole是一种小分子放射增敏剂，已被证明是一种有效且无毒的人宫颈、头颈部鳞状细胞癌缺氧标记物（Hypoxia maker）。由于其化学稳定性，且自由渗透进入脑和脑肿瘤组织，盐酸匹莫硝唑（Pimonidazole Hydrochloride）缺氧标记物已被广泛用于实验和临床研究。 Pimonidazole HCl呈弱碱性盐酸盐，水溶性非常好，水溶性为400mM（=116 mg/ml），建议溶解于116mg/ml 的中性生理盐水。

Hypoxyprobe, Inc. is a small company dedicated to providing tools for the diagnosis and treatment of malignant and normal tissue diseases in which oxygen regulation is disturbed. The company is located at 121 Middlesex Turnpike, Burlington, Massachusetts, USA 01803 and is a spin-off of the Hypoxyprobe Division of Natural Pharmacia International, Inc. (NPI).

Hypoxyprobe, Inc. arose from a collaboration between Dr. James Raleigh in the Department of Radiation Oncology at the University of North Carolina at Chapel Hill and NPI which at the time was located in the Research Triangle Park, North Carolina.

The collaboration between UNC Chapel Hill and NPI at first focused on clinical studies of tumor hypoxia. NPI manufactured pimonidazole HCl on a large scale and Dr. Raleigh provided patented antibody reagents for detecting the binding of pimonidazole to hypoxic cells in human tumors.

Preclinical studies in dogs, rats and mice generated a growing interest among the scientific community in pimonidazole HCl as a hypoxia marker in general and in 2002 NPI issued a five-year exclusive license to Chemicon International to market a limited line of Hypoxyprobe reagents for animal use. In 2006, anticipating a need for an expanded line of Hypoxyprobe reagents, NPI ended Chemicon抯 license and established Hypoxyprobe, Inc. to develop an enhanced line of reagents for both animal and clinical studies.

The Company is now focused on developing non-invasive hypoxia markers and hypoxia dependent cytotoxins based on the pimonidazole core structure.

Hypoxyprobe常卖产品：

靶点科技（北京）有限公司是Hypoxyprob在中国的代理。被授权在中国负责品牌宣传推广，产品售前咨询和售后服务等一切商业活动和行为。靶点科技有专业技术团队，竭力为广大中国客户提供全方位的产品和服务赋能支持。

Hypoxyprobe官网中文网站：筹备中……

Hypoxyprobe官网英文网站：www.hypoxyprobe.com